Key Highlights

● Health insurers extended a slide on a proposal to widen Medicare Advantage audits.

● UnitedHealth closed at its lowest level since April.

● Insmed soared on an unconfirmed report that Sanofi is evaluating a bid.

● The S&P 500 fell for a sixth straight session.

Managed-care stocks extended a punishing slide on Thursday as investors kept digesting a federal proposal to widen Medicare Advantage audits, and the selling spilled across the wider health care sector.

Insurers in the crosshairs again

Health care was one of the heavier weights on Wall Street on Thursday, November 19, and once again the damage was concentrated in health insurers. The pressure traces back to a proposal from the Centers for Medicare & Medicaid Services, the federal agency that runs Medicare, to widen audits of Medicare Advantage plans. It is a regulatory proposal that applies to the whole industry rather than to any single company, but investors have treated it as a potential headwind for every insurer with a large Medicare Advantage book.

UnitedHealth (NYSE:UNH) Group the largest of them, tumbled again after a steep drop on Wednesday, extending a sharp three-day slide and closing at its lowest level since April. UnitedHealth was a major reason the Dow Jones Industrial Average lost 1,101.11 points to 49,097.06.

Humana (NYSE:HUM), Elevance Health (NYSE:ELV) and Centene (NYSE:CNC) all fell again after heavy losses the day before. Universal Health Services (NYSE:UHS) a hospital operator rather than an insurer, sank sharply too. The move was tied to the same managed-care selling.

Selling spreads beyond managed care

The weakness was not confined to insurers. Zoetis (NYSE:ZTS) the animal-health company, slumped. Eli Lilly (NYSE:LLY) slid, and Johnson & Johnson (NYSE:JNJ) and Merck (NYSE:MRK) both weighed on the Dow.

Health care was among the worse performers on a day when nearly all 11 S&P 500 sectors fell. The S&P 500 dropped 147.80 points to 7,175.83 for its sixth straight loss.

One dramatic exception

The sector's standout came from a Takeover report. Insmed (NASDAQ:INSM) soared after a media report, citing people familiar with the matter, said Sanofi (NASDAQ:SNY) is evaluating an Acquisition of the company and working with advisers. The report was unconfirmed. No deal has been agreed, the talks may not lead to a transaction, and neither company commented. Insmed's jump briefly triggered a Volatility halt. Sanofi's US-listed shares slipped.

Insmed's surge underlined how narrow the day's gains were. On the S&P 500, decliners outnumbered advancers by 464 to 37 or 38.

Why the audit proposal matters to investors

Medicare Advantage is a large and profitable Business line for the biggest insurers, which run private plans for seniors on the government's behalf. Wider audits could, in principle, change how payments to those plans are reviewed, and that uncertainty is what markets appear to be pricing. Because the proposal is still a proposal, its final shape is not yet known, and analysts and companies will have to wait for the regulatory process to play out.

What to watch

Investors will be watching for any formal comment from insurers on the CMS proposal, along with signals on how and when the agency might finalise it. For Insmed, the focus is whether Sanofi or any other party confirms talks. On the macro side, the Federal Reserve's December 8–9 meeting and November Inflation data on December 10 will shape the mood for defensive sectors such as health care.